Serotonin decreases HIV-1 replication in primary cultures of human macrophages through 5-HT1A receptors
Identifieur interne : 002920 ( Pmc/Checkpoint ); précédent : 002919; suivant : 002921Serotonin decreases HIV-1 replication in primary cultures of human macrophages through 5-HT1A receptors
Auteurs : B. Manéglier [France] ; G J Guillemin [Australie] ; P. Clayette [France] ; C. Rogez-Kreuz [France] ; B J Brew [Australie] ; D. Dormont [France] ; C. Advenier [France] ; P. Therond [France] ; O. Spreux-Varoquaux [France]Source :
- British Journal of Pharmacology [ 0007-1188 ] ; 2008.
Abstract
Url:
DOI: 10.1038/bjp.2008.80
PubMed: 18332855
PubMed Central: 2438982
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
PMC:2438982Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Serotonin decreases HIV-1 replication in primary cultures of human macrophages through 5-HT<sub>1A</sub> receptors</title><author><name sortKey="Maneglier, B" sort="Maneglier, B" uniqKey="Maneglier B" first="B" last="Manéglier">B. Manéglier</name><affiliation wicri:level="1"><nlm:aff id="aff1"><institution>UPRES EA 220, UFR Médicale Paris-Ile de France-Ouest, Université Versailles St-Quentin</institution> Saint-Quentin en Yvelines,<country>France</country></nlm:aff><country xml:lang="fr">France</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation><affiliation wicri:level="1"><nlm:aff id="aff2"><institution>Unité de Pharmacologie, Service de Biologie, Centre Hospitalier de Versailles</institution> Le Chesnay,<country>France</country></nlm:aff><country xml:lang="fr">France</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation><affiliation wicri:level="1"><nlm:aff id="aff3"><institution>Commissariat à l'Energie Atomique (CEA), Service de Neurovirologie, Institut Paris Sud Cytokine (IPSC), UMR E01 Université Paris XI</institution> Fontenay-aux-Roses,<country>France</country></nlm:aff><country xml:lang="fr">France</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Guillemin, G J" sort="Guillemin, G J" uniqKey="Guillemin G" first="G J" last="Guillemin">G J Guillemin</name><affiliation wicri:level="1"><nlm:aff id="aff4"><institution>Faculty of Medicine, University of New South Wales</institution> Sydney, New South Wales,<country>Australia</country></nlm:aff><country xml:lang="fr">Australie</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Clayette, P" sort="Clayette, P" uniqKey="Clayette P" first="P" last="Clayette">P. Clayette</name><affiliation wicri:level="1"><nlm:aff id="aff5"><institution>Laboratoire de Neurovirologie, SPI-BIO, Commissariat à l'Energie Atomique</institution> Fontenay-aux-Roses,<country>France</country></nlm:aff><country xml:lang="fr">France</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Rogez Kreuz, C" sort="Rogez Kreuz, C" uniqKey="Rogez Kreuz C" first="C" last="Rogez-Kreuz">C. Rogez-Kreuz</name><affiliation wicri:level="1"><nlm:aff id="aff5"><institution>Laboratoire de Neurovirologie, SPI-BIO, Commissariat à l'Energie Atomique</institution> Fontenay-aux-Roses,<country>France</country></nlm:aff><country xml:lang="fr">France</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Brew, B J" sort="Brew, B J" uniqKey="Brew B" first="B J" last="Brew">B J Brew</name><affiliation wicri:level="1"><nlm:aff id="aff4"><institution>Faculty of Medicine, University of New South Wales</institution> Sydney, New South Wales,<country>Australia</country></nlm:aff><country xml:lang="fr">Australie</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Dormont, D" sort="Dormont, D" uniqKey="Dormont D" first="D" last="Dormont">D. Dormont</name><affiliation wicri:level="1"><nlm:aff id="aff3"><institution>Commissariat à l'Energie Atomique (CEA), Service de Neurovirologie, Institut Paris Sud Cytokine (IPSC), UMR E01 Université Paris XI</institution> Fontenay-aux-Roses,<country>France</country></nlm:aff><country xml:lang="fr">France</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Advenier, C" sort="Advenier, C" uniqKey="Advenier C" first="C" last="Advenier">C. Advenier</name><affiliation wicri:level="1"><nlm:aff id="aff1"><institution>UPRES EA 220, UFR Médicale Paris-Ile de France-Ouest, Université Versailles St-Quentin</institution> Saint-Quentin en Yvelines,<country>France</country></nlm:aff><country xml:lang="fr">France</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation><affiliation wicri:level="1"><nlm:aff id="aff2"><institution>Unité de Pharmacologie, Service de Biologie, Centre Hospitalier de Versailles</institution> Le Chesnay,<country>France</country></nlm:aff><country xml:lang="fr">France</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Therond, P" sort="Therond, P" uniqKey="Therond P" first="P" last="Therond">P. Therond</name><affiliation wicri:level="1"><nlm:aff id="aff2"><institution>Unité de Pharmacologie, Service de Biologie, Centre Hospitalier de Versailles</institution> Le Chesnay,<country>France</country></nlm:aff><country xml:lang="fr">France</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Spreux Varoquaux, O" sort="Spreux Varoquaux, O" uniqKey="Spreux Varoquaux O" first="O" last="Spreux-Varoquaux">O. Spreux-Varoquaux</name><affiliation wicri:level="1"><nlm:aff id="aff1"><institution>UPRES EA 220, UFR Médicale Paris-Ile de France-Ouest, Université Versailles St-Quentin</institution> Saint-Quentin en Yvelines,<country>France</country></nlm:aff><country xml:lang="fr">France</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation><affiliation wicri:level="1"><nlm:aff id="aff2"><institution>Unité de Pharmacologie, Service de Biologie, Centre Hospitalier de Versailles</institution> Le Chesnay,<country>France</country></nlm:aff><country xml:lang="fr">France</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">18332855</idno><idno type="pmc">2438982</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2438982</idno><idno type="RBID">PMC:2438982</idno><idno type="doi">10.1038/bjp.2008.80</idno><date when="2008">2008</date><idno type="wicri:Area/Pmc/Corpus">000017</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000017</idno><idno type="wicri:Area/Pmc/Curation">000017</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000017</idno><idno type="wicri:Area/Pmc/Checkpoint">002920</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">002920</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Serotonin decreases HIV-1 replication in primary cultures of human macrophages through 5-HT<sub>1A</sub> receptors</title><author><name sortKey="Maneglier, B" sort="Maneglier, B" uniqKey="Maneglier B" first="B" last="Manéglier">B. Manéglier</name><affiliation wicri:level="1"><nlm:aff id="aff1"><institution>UPRES EA 220, UFR Médicale Paris-Ile de France-Ouest, Université Versailles St-Quentin</institution> Saint-Quentin en Yvelines,<country>France</country></nlm:aff><country xml:lang="fr">France</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation><affiliation wicri:level="1"><nlm:aff id="aff2"><institution>Unité de Pharmacologie, Service de Biologie, Centre Hospitalier de Versailles</institution> Le Chesnay,<country>France</country></nlm:aff><country xml:lang="fr">France</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation><affiliation wicri:level="1"><nlm:aff id="aff3"><institution>Commissariat à l'Energie Atomique (CEA), Service de Neurovirologie, Institut Paris Sud Cytokine (IPSC), UMR E01 Université Paris XI</institution> Fontenay-aux-Roses,<country>France</country></nlm:aff><country xml:lang="fr">France</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Guillemin, G J" sort="Guillemin, G J" uniqKey="Guillemin G" first="G J" last="Guillemin">G J Guillemin</name><affiliation wicri:level="1"><nlm:aff id="aff4"><institution>Faculty of Medicine, University of New South Wales</institution> Sydney, New South Wales,<country>Australia</country></nlm:aff><country xml:lang="fr">Australie</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Clayette, P" sort="Clayette, P" uniqKey="Clayette P" first="P" last="Clayette">P. Clayette</name><affiliation wicri:level="1"><nlm:aff id="aff5"><institution>Laboratoire de Neurovirologie, SPI-BIO, Commissariat à l'Energie Atomique</institution> Fontenay-aux-Roses,<country>France</country></nlm:aff><country xml:lang="fr">France</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Rogez Kreuz, C" sort="Rogez Kreuz, C" uniqKey="Rogez Kreuz C" first="C" last="Rogez-Kreuz">C. Rogez-Kreuz</name><affiliation wicri:level="1"><nlm:aff id="aff5"><institution>Laboratoire de Neurovirologie, SPI-BIO, Commissariat à l'Energie Atomique</institution> Fontenay-aux-Roses,<country>France</country></nlm:aff><country xml:lang="fr">France</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Brew, B J" sort="Brew, B J" uniqKey="Brew B" first="B J" last="Brew">B J Brew</name><affiliation wicri:level="1"><nlm:aff id="aff4"><institution>Faculty of Medicine, University of New South Wales</institution> Sydney, New South Wales,<country>Australia</country></nlm:aff><country xml:lang="fr">Australie</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Dormont, D" sort="Dormont, D" uniqKey="Dormont D" first="D" last="Dormont">D. Dormont</name><affiliation wicri:level="1"><nlm:aff id="aff3"><institution>Commissariat à l'Energie Atomique (CEA), Service de Neurovirologie, Institut Paris Sud Cytokine (IPSC), UMR E01 Université Paris XI</institution> Fontenay-aux-Roses,<country>France</country></nlm:aff><country xml:lang="fr">France</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Advenier, C" sort="Advenier, C" uniqKey="Advenier C" first="C" last="Advenier">C. Advenier</name><affiliation wicri:level="1"><nlm:aff id="aff1"><institution>UPRES EA 220, UFR Médicale Paris-Ile de France-Ouest, Université Versailles St-Quentin</institution> Saint-Quentin en Yvelines,<country>France</country></nlm:aff><country xml:lang="fr">France</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation><affiliation wicri:level="1"><nlm:aff id="aff2"><institution>Unité de Pharmacologie, Service de Biologie, Centre Hospitalier de Versailles</institution> Le Chesnay,<country>France</country></nlm:aff><country xml:lang="fr">France</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Therond, P" sort="Therond, P" uniqKey="Therond P" first="P" last="Therond">P. Therond</name><affiliation wicri:level="1"><nlm:aff id="aff2"><institution>Unité de Pharmacologie, Service de Biologie, Centre Hospitalier de Versailles</institution> Le Chesnay,<country>France</country></nlm:aff><country xml:lang="fr">France</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Spreux Varoquaux, O" sort="Spreux Varoquaux, O" uniqKey="Spreux Varoquaux O" first="O" last="Spreux-Varoquaux">O. Spreux-Varoquaux</name><affiliation wicri:level="1"><nlm:aff id="aff1"><institution>UPRES EA 220, UFR Médicale Paris-Ile de France-Ouest, Université Versailles St-Quentin</institution> Saint-Quentin en Yvelines,<country>France</country></nlm:aff><country xml:lang="fr">France</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation><affiliation wicri:level="1"><nlm:aff id="aff2"><institution>Unité de Pharmacologie, Service de Biologie, Centre Hospitalier de Versailles</institution> Le Chesnay,<country>France</country></nlm:aff><country xml:lang="fr">France</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author></analytic><series><title level="j">British Journal of Pharmacology</title><idno type="ISSN">0007-1188</idno><idno type="eISSN">1476-5381</idno><imprint><date when="2008">2008</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><bold>Background and purpose:</bold> 5-HT (serotonin) is known to be involved in neuroinflammation and immunoregulation. The human immunodeficiency virus (HIV) targets cells such as monocytes/macrophages, which colocalize with 5-HT-releasing cell types, mostly platelets. In this study, we investigated the effects of 5-HT on HIV-1-infected macrophages <italic>in vitro</italic>.</p><p><bold>Experimental approach:</bold> Human macrophages cultured in serum-free medium were treated over 7 days with 5-HT at three concentrations (0.01, 1 and 100 μ<sc>M</sc>) with or without agonists and antagonists of 5-HT<sub>1A</sub> and 5-HT<sub>2</sub> receptors. After 7 days of treatment, macrophages were infected with HIV-1/Ba-L and virus replication was monitored over 16 days and expression of proviral HIV DNA was investigated by PCR after 24 h of infection. Cell surface expression of HIV-1/Ba-L receptor (CD4) and coreceptor (CCR5) was investigated by flow cytometry. The CCR5 ligand, macrophage inflammatory protein-1α (MIP-1α), was quantified by ELISA in cell culture supernatants and MIP-1α mRNA expression was assessed by reverse transcriptase-PCR.</p><p><bold>Key results:</bold> <italic>In vitro</italic>, 5-HT downregulated the membranous expression of CCR5 and led to a decrease of HIV-1 infection, probably through its action on 5-HT<sub>1A</sub> receptors. 5-HT (100 μ<sc>M</sc>) was also able to induce overexpression of MIP-1α mRNA leading to an increase of MIP-1α secretion by human macrophages.</p><p><bold>Conclusions and implications:</bold> The effects of 5-HT on HIV infection could be a consequence of the increase in MIP-1α concentrations and/or CCR5 receptor downregulation. These results suggest that 5-HT can inhibit the replication of HIV-1 in primary culture of human macrophages through its action on 5-HT<sub>1A</sub> receptors.</p></div></front></TEI><pmc article-type="other"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<pmc-comment> Original-type: rq</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Pharmacol</journal-id><journal-title>British Journal of Pharmacology</journal-title><issn pub-type="ppub">0007-1188</issn><issn pub-type="epub">1476-5381</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">18332855</article-id><article-id pub-id-type="pmc">2438982</article-id><article-id pub-id-type="pii">bjp200880</article-id><article-id pub-id-type="doi">10.1038/bjp.2008.80</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Papers</subject><subj-group><subject>Immunopharmacology and Inflammation</subject></subj-group></subj-group></article-categories><title-group><article-title>Serotonin decreases HIV-1 replication in primary cultures of human macrophages through 5-HT<sub>1A</sub> receptors</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Manéglier</surname><given-names>B</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="corresp" rid="caf1">*</xref></contrib><contrib contrib-type="author"><name><surname>Guillemin</surname><given-names>G J</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Clayette</surname><given-names>P</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Rogez-Kreuz</surname><given-names>C</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Brew</surname><given-names>B J</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Dormont</surname><given-names>D</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="author-notes" rid="note1">✠</xref></contrib><contrib contrib-type="author"><name><surname>Advenier</surname><given-names>C</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Therond</surname><given-names>P</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Spreux-Varoquaux</surname><given-names>O</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref></contrib></contrib-group><aff id="aff1"><label>1</label><institution>UPRES EA 220, UFR Médicale Paris-Ile de France-Ouest, Université Versailles St-Quentin</institution> Saint-Quentin en Yvelines,<country>France</country></aff><aff id="aff2"><label>2</label><institution>Unité de Pharmacologie, Service de Biologie, Centre Hospitalier de Versailles</institution> Le Chesnay,<country>France</country></aff><aff id="aff3"><label>3</label><institution>Commissariat à l'Energie Atomique (CEA), Service de Neurovirologie, Institut Paris Sud Cytokine (IPSC), UMR E01 Université Paris XI</institution> Fontenay-aux-Roses,<country>France</country></aff><aff id="aff4"><label>4</label><institution>Faculty of Medicine, University of New South Wales</institution> Sydney, New South Wales,<country>Australia</country></aff><aff id="aff5"><label>5</label><institution>Laboratoire de Neurovirologie, SPI-BIO, Commissariat à l'Energie Atomique</institution> Fontenay-aux-Roses,<country>France</country></aff><author-notes><corresp id="caf1"><label>*</label>Author for correspondence: <email xlink:href="mailto:bmaneglier@ch-versailles.fr">bmaneglier@ch-versailles.fr</email></corresp><fn fn-type="present-address" id="note1"><label>✠</label><p>Deceased.</p></fn></author-notes><pub-date pub-type="epub"><day>10</day><month>03</month><year>2008</year></pub-date><pub-date pub-type="collection"><day>28</day><month>04</month><year>2008</year></pub-date><pub-date pub-type="ppub"><month>5</month><year>2008</year></pub-date><volume>154</volume><issue>1</issue><fpage>174</fpage><lpage>182</lpage><history><date date-type="received"><day>28</day><month>01</month><year>2008</year></date><date date-type="accepted"><day>06</day><month>02</month><year>2008</year></date></history><copyright-statement>Copyright 2008, Nature Publishing Group</copyright-statement><copyright-year>2008</copyright-year><permissions><copyright-holder>Nature Publishing Group</copyright-holder></permissions><abstract><p><bold>Background and purpose:</bold> 5-HT (serotonin) is known to be involved in neuroinflammation and immunoregulation. The human immunodeficiency virus (HIV) targets cells such as monocytes/macrophages, which colocalize with 5-HT-releasing cell types, mostly platelets. In this study, we investigated the effects of 5-HT on HIV-1-infected macrophages <italic>in vitro</italic>.</p><p><bold>Experimental approach:</bold> Human macrophages cultured in serum-free medium were treated over 7 days with 5-HT at three concentrations (0.01, 1 and 100 μ<sc>M</sc>) with or without agonists and antagonists of 5-HT<sub>1A</sub> and 5-HT<sub>2</sub> receptors. After 7 days of treatment, macrophages were infected with HIV-1/Ba-L and virus replication was monitored over 16 days and expression of proviral HIV DNA was investigated by PCR after 24 h of infection. Cell surface expression of HIV-1/Ba-L receptor (CD4) and coreceptor (CCR5) was investigated by flow cytometry. The CCR5 ligand, macrophage inflammatory protein-1α (MIP-1α), was quantified by ELISA in cell culture supernatants and MIP-1α mRNA expression was assessed by reverse transcriptase-PCR.</p><p><bold>Key results:</bold> <italic>In vitro</italic>, 5-HT downregulated the membranous expression of CCR5 and led to a decrease of HIV-1 infection, probably through its action on 5-HT<sub>1A</sub> receptors. 5-HT (100 μ<sc>M</sc>) was also able to induce overexpression of MIP-1α mRNA leading to an increase of MIP-1α secretion by human macrophages.</p><p><bold>Conclusions and implications:</bold> The effects of 5-HT on HIV infection could be a consequence of the increase in MIP-1α concentrations and/or CCR5 receptor downregulation. These results suggest that 5-HT can inhibit the replication of HIV-1 in primary culture of human macrophages through its action on 5-HT<sub>1A</sub> receptors.</p></abstract><kwd-group><kwd>HIV</kwd><kwd>macrophages</kwd><kwd>5-HT/serotonin</kwd><kwd>5-HT<sub>1A</sub> receptor subtypes</kwd><kwd>CCR5</kwd></kwd-group></article-meta></front><floats-wrap><fig id="fig1"><label>Figure 1</label><caption><p>Effects of a long-term treatment with 5-HT (0.01, 1 and 100 μ<sc>M</sc>) on HIV-1/Ba-L replication in primary cultures of human monocyte-derived macrophages. Cells were treated with 5-HT before, during or after infection with HIV-1/Ba-L at a multiplicity of infection of 1. Treatments were maintained until the peak of HIV replication was observed 16 days after infection. Results are presented as the cumulative values of reverse transcriptase (RT) activity (expressed in ng ml<sup>−1</sup> of RT) until day 16 post-infection. Results are expressed as means±s.d. of three independent experiments performed in triplicate.</p></caption><graphic mime-subtype="eps" xlink:href="bjp200880f1"></graphic></fig><fig id="fig2"><label>Figure 2</label><caption><p>Effects of 5-HT and 5-HT receptor agonists on HIV proviral DNA in primary cultures of human monocyte-derived macrophages (MdM). MdM treated during 7 days with 5-HT (0.01, 1 or 100 μ<sc>M</sc>), WAY100635 (10 μ<sc>M</sc>), 5-HT (100 μ<sc>M</sc>)+WAY100635 (10 μ<sc>M</sc>), 8-OH DPAT (50 μ<sc>M</sc>) or αCH<sub>3</sub>-5-HT (50 μ<sc>M</sc>) were infected with HIV-1/Ba-L (multiplicity of infection of 1) for 24 h. Two dilutions of each DNA sample were performed and the <italic>gag</italic> (SK38-SK39) and β-globin genes were amplified by PCR. There are eight different experimental conditions: (1) untreated MdM; (2) 5-HT-treated MdM (100 μ<sc>M</sc>); (3) 5-HT-treated MdM (1 μ<sc>M</sc>); (4) 5-HT-treated MdM (0.01 μ<sc>M</sc>); (5) WAY100635-treated MdM (10 μ<sc>M</sc>); (6) 5-HT+WAY100635-treated MdM (100 and 10 μ<sc>M</sc>, respectively); (7) 8-OH-DPAT-treated MdM (50 μ<sc>M</sc>) and (8) αCH<sub>3</sub>-5-HT (50 μ<sc>M</sc>). This experiment was repeated twice, with blood from two different donors, and similar results were obtained in each case.</p></caption><graphic mime-subtype="eps" xlink:href="bjp200880f2"></graphic></fig><fig id="fig3"><label>Figure 3</label><caption><p>Effects of 5-HT on CD4 (<bold>a</bold>) and CCR5 (<bold>b</bold>) cell membrane expression in human monocyte-derived macrophages (MdM). Histograms represent the intensity of fluorescence expressed in molecules of equivalent fluorochrome (MEF). Lines with open circles represent percentages of positive cells for CD4 (<bold>a</bold>) and for CCR5 (<bold>b</bold>) biomarkers. Results are expressed as means±s.d. for six culture wells of MdM and were generated from blood samples taken from three donors. For the expression of CCR5 at the MdM membrane, differences were considered as significant with <sup>*</sup><italic>P</italic>=0.008, <sup>**</sup><italic>P</italic>=0.03, <sup>***</sup><italic>P</italic>=0.05 and <sup>****</sup><italic>P</italic>=0.007.</p></caption><graphic mime-subtype="eps" xlink:href="bjp200880f3"></graphic></fig><fig id="fig4"><label>Figure 4</label><caption><p>(<bold>a</bold>) Effects of 5-HT on macrophage inflammatory protein-1α (MIP-1α) secretion in primary cultures of human monocyte-derived macrophages (MdM). MIP-1α was quantified by ELISA in the supernatants of cells treated for 7 days with 5-HT (100 μ<sc>M</sc>), 8-OH DPAT (50 μ<sc>M</sc>), WAY100635 (10 μ<sc>M</sc>) and 5-HT+WAY100635 (100 and 10 μ<sc>M</sc>, respectively). (<bold>b</bold>) Effects of 5-HT on MIP-1α mRNA production in primary cultures of human MdM. MIP-1α mRNA was quantified by reverse transcription-PCR. Human MdM were treated during 7 days with 5-HT (100 μ<sc>M</sc>), 5-HT+SB 203580 (100 and 10 μ<sc>M</sc>, respectively), 8-OH DPAT (50 μ<sc>M</sc>), 8-OH DPAT+SB 203580 (50 and 10 μ<sc>M</sc>, respectively) or SB 203580 (10 μ<sc>M</sc>) before total RNA extraction. mRNA levels were normalized on the basis of glyceraldehyde-3-phosphate dehydrogenase mRNA levels. Results, expressed as means±s.d., are representative of those obtained with samples from three blood donors.</p></caption><graphic mime-subtype="eps" xlink:href="bjp200880f4"></graphic></fig><fig id="fig5"><label>Figure 5</label><caption><p>Scheme of effects of 5-HT on HIV-1 replication in primary cultures of human monocyte-derived macrophages (MdM), through the involvement of 5-HT<sub>1A</sub> receptors. MIP-1α, macrophage inflammatory protein-1α.</p></caption><graphic mime-subtype="tiff" xlink:href="bjp200880f5"></graphic></fig></floats-wrap></pmc><affiliations><list><country><li>Australie</li><li>France</li></country></list><tree><country name="France"><noRegion><name sortKey="Maneglier, B" sort="Maneglier, B" uniqKey="Maneglier B" first="B" last="Manéglier">B. Manéglier</name></noRegion><name sortKey="Advenier, C" sort="Advenier, C" uniqKey="Advenier C" first="C" last="Advenier">C. Advenier</name><name sortKey="Advenier, C" sort="Advenier, C" uniqKey="Advenier C" first="C" last="Advenier">C. Advenier</name><name sortKey="Clayette, P" sort="Clayette, P" uniqKey="Clayette P" first="P" last="Clayette">P. Clayette</name><name sortKey="Dormont, D" sort="Dormont, D" uniqKey="Dormont D" first="D" last="Dormont">D. Dormont</name><name sortKey="Maneglier, B" sort="Maneglier, B" uniqKey="Maneglier B" first="B" last="Manéglier">B. Manéglier</name><name sortKey="Maneglier, B" sort="Maneglier, B" uniqKey="Maneglier B" first="B" last="Manéglier">B. Manéglier</name><name sortKey="Rogez Kreuz, C" sort="Rogez Kreuz, C" uniqKey="Rogez Kreuz C" first="C" last="Rogez-Kreuz">C. Rogez-Kreuz</name><name sortKey="Spreux Varoquaux, O" sort="Spreux Varoquaux, O" uniqKey="Spreux Varoquaux O" first="O" last="Spreux-Varoquaux">O. Spreux-Varoquaux</name><name sortKey="Spreux Varoquaux, O" sort="Spreux Varoquaux, O" uniqKey="Spreux Varoquaux O" first="O" last="Spreux-Varoquaux">O. Spreux-Varoquaux</name><name sortKey="Therond, P" sort="Therond, P" uniqKey="Therond P" first="P" last="Therond">P. Therond</name></country><country name="Australie"><noRegion><name sortKey="Guillemin, G J" sort="Guillemin, G J" uniqKey="Guillemin G" first="G J" last="Guillemin">G J Guillemin</name></noRegion><name sortKey="Brew, B J" sort="Brew, B J" uniqKey="Brew B" first="B J" last="Brew">B J Brew</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Pmc/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002920 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Checkpoint/biblio.hfd -nk 002920 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Pmc
|étape= Checkpoint
|type= RBID
|clé= PMC:2438982
|texte= Serotonin decreases HIV-1 replication in primary cultures of human macrophages through 5-HT1A receptors
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Checkpoint/RBID.i -Sk "pubmed:18332855" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |